Evolent Health Stock Plummets to New 52-Week Low at $6.50

Evolent Health, Inc. has reached a new 52-week low, trading at USD 6.50 as of November 3, 2025. This marks a significant decline for the microcap company, which has seen its stock price plummet by 71.67% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
The company's market capitalization stands at approximately USD 1,151 million, placing it within the small-cap category. Evolent Health has reported negative financial results for three consecutive quarters, with a pre-tax profit of USD -7.73 million and a net profit of USD -6.9 million, reflecting substantial declines of 355.12% and 311.27%, respectively. Additionally, the company's operating cash flow has reached a low of USD -33.32 million.

With a return on equity of -10.28% and a price-to-book ratio of 1.28, Evolent Health's financial metrics indicate ongoing challenges. The stock's performance has consistently underperformed against the S&P 500 over the last three years, highlighting a trend of significant financial difficulties for the company.